Axitinib

Axitinib (Inlyta, Pfizer Europe MA EEIG) has 1 EU-approved indication in 1 tumour type.
Approved indications of Axitinib
Biomarker requirementRegimenSettingConditions
Renal cell carcinoma1
None
Monotherapy
2L
advanced
Failure of prior treatment with sunitinib or a cytokine
Full text of section 4.1 (therapeutic indications)

Inlyta is indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of prior treatment with sunitinib or a cytokine.

Label history

16 changes to the Inlyta label since 2013, none of them to the indications. Newest first, in the words of EMA's record of each procedure.

Changes